newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT

– Top-line Results Expected in the Fourth Quarter of 2023 – – Phase 1/2 Data Demonstrated Vimseltinib's Best-in-Class Potential for the Treatment of TGCT – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a